Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies
IntroductionStudying antibody dynamics following re-exposure to infection and/or vaccination is crucial for a better understanding of fundamental immunological processes, vaccine development, and health policy research.MethodsWe adopted a nonlinear mixed modeling approach based on ordinary different...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1104605/full |
| _version_ | 1797904915832504320 |
|---|---|
| author | Hajar Besbassi Hajar Besbassi Hajar Besbassi Irene Garcia-Fogeda Mark Quinlivan Judy Breuer Steven Abrams Steven Abrams Niel Hens Niel Hens Benson Ogunjimi Benson Ogunjimi Benson Ogunjimi Benson Ogunjimi Philippe Beutels |
| author_facet | Hajar Besbassi Hajar Besbassi Hajar Besbassi Irene Garcia-Fogeda Mark Quinlivan Judy Breuer Steven Abrams Steven Abrams Niel Hens Niel Hens Benson Ogunjimi Benson Ogunjimi Benson Ogunjimi Benson Ogunjimi Philippe Beutels |
| author_sort | Hajar Besbassi |
| collection | DOAJ |
| description | IntroductionStudying antibody dynamics following re-exposure to infection and/or vaccination is crucial for a better understanding of fundamental immunological processes, vaccine development, and health policy research.MethodsWe adopted a nonlinear mixed modeling approach based on ordinary differential equations (ODE) to characterize varicella-zoster virus specific antibody dynamics during and after clinical herpes zoster. Our ODEs models convert underlying immunological processes into mathematical formulations, allowing for testable data analysis. In order to cope with inter- and intra-individual variability, mixed models include population-averaged parameters (fixed effects) and individual-specific parameters (random effects). We explored the use of various ODE-based nonlinear mixed models to describe longitudinally collected markers of immunological response in 61 herpes zoster patients.ResultsStarting from a general formulation of such models, we study different plausible processes underlying observed antibody titer concentrations over time, including various individual-specific parameters. Among the converged models, the best fitting and most parsimonious model implies that once Varicella-zoster virus (VZV) reactivation is clinically apparent (i.e., Herpes-zoster (HZ) can be diagnosed), short-living and long-living antibody secreting cells (SASC and LASC, respectively) will not expand anymore. Additionally, we investigated the relationship between age and viral load on SASC using a covariate model to gain a deeper understanding of the population’s characteristics.ConclusionThe results of this study provide crucial and unique insights that can aid in improving our understanding of VZV antibody dynamics and in making more accurate projections regarding the potential impact of vaccines. |
| first_indexed | 2024-04-10T09:56:37Z |
| format | Article |
| id | doaj.art-6bc551d73d25444bb0a1196312627be4 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T09:56:37Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6bc551d73d25444bb0a1196312627be42023-02-16T12:22:08ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-02-011410.3389/fimmu.2023.11046051104605Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodiesHajar Besbassi0Hajar Besbassi1Hajar Besbassi2Irene Garcia-Fogeda3Mark Quinlivan4Judy Breuer5Steven Abrams6Steven Abrams7Niel Hens8Niel Hens9Benson Ogunjimi10Benson Ogunjimi11Benson Ogunjimi12Benson Ogunjimi13Philippe Beutels14Centre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, BelgiumAntwerp Center for Translational Immunology and Virology (ACTIV), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumCentre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumDivision of Infection and Immunity, University College London, London, United KingdomDivision of Infection and Immunity, University College London, London, United KingdomGlobal Health Institute (GHI), Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, BelgiumData Science Institute (DSI), Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), UHasselt, Hasselt, BelgiumCentre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumData Science Institute (DSI), Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), UHasselt, Hasselt, BelgiumCentre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumAntwerp Unit for Data Analysis and Computation in Immunology and Sequencing (AUDACIS), University of Antwerp, Antwerp, BelgiumAntwerp Center for Translational Immunology and Virology (ACTIV), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumDepartment of Paediatrics, Antwerp University Hospital, Edegem, BelgiumCentre for Health Economics Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, BelgiumIntroductionStudying antibody dynamics following re-exposure to infection and/or vaccination is crucial for a better understanding of fundamental immunological processes, vaccine development, and health policy research.MethodsWe adopted a nonlinear mixed modeling approach based on ordinary differential equations (ODE) to characterize varicella-zoster virus specific antibody dynamics during and after clinical herpes zoster. Our ODEs models convert underlying immunological processes into mathematical formulations, allowing for testable data analysis. In order to cope with inter- and intra-individual variability, mixed models include population-averaged parameters (fixed effects) and individual-specific parameters (random effects). We explored the use of various ODE-based nonlinear mixed models to describe longitudinally collected markers of immunological response in 61 herpes zoster patients.ResultsStarting from a general formulation of such models, we study different plausible processes underlying observed antibody titer concentrations over time, including various individual-specific parameters. Among the converged models, the best fitting and most parsimonious model implies that once Varicella-zoster virus (VZV) reactivation is clinically apparent (i.e., Herpes-zoster (HZ) can be diagnosed), short-living and long-living antibody secreting cells (SASC and LASC, respectively) will not expand anymore. Additionally, we investigated the relationship between age and viral load on SASC using a covariate model to gain a deeper understanding of the population’s characteristics.ConclusionThe results of this study provide crucial and unique insights that can aid in improving our understanding of VZV antibody dynamics and in making more accurate projections regarding the potential impact of vaccines.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1104605/fullvaricella zoster virusherpes zosterantibody levelsordinary differential equationsnonlinear mixed-effects modelsmathematical modeling |
| spellingShingle | Hajar Besbassi Hajar Besbassi Hajar Besbassi Irene Garcia-Fogeda Mark Quinlivan Judy Breuer Steven Abrams Steven Abrams Niel Hens Niel Hens Benson Ogunjimi Benson Ogunjimi Benson Ogunjimi Benson Ogunjimi Philippe Beutels Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies Frontiers in Immunology varicella zoster virus herpes zoster antibody levels ordinary differential equations nonlinear mixed-effects models mathematical modeling |
| title | Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies |
| title_full | Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies |
| title_fullStr | Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies |
| title_full_unstemmed | Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies |
| title_short | Modeling antibody dynamics following herpes zoster indicates that higher varicella-zoster virus viremia generates more VZV-specific antibodies |
| title_sort | modeling antibody dynamics following herpes zoster indicates that higher varicella zoster virus viremia generates more vzv specific antibodies |
| topic | varicella zoster virus herpes zoster antibody levels ordinary differential equations nonlinear mixed-effects models mathematical modeling |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1104605/full |
| work_keys_str_mv | AT hajarbesbassi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT hajarbesbassi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT hajarbesbassi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT irenegarciafogeda modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT markquinlivan modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT judybreuer modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT stevenabrams modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT stevenabrams modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT nielhens modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT nielhens modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT bensonogunjimi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT bensonogunjimi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT bensonogunjimi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT bensonogunjimi modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies AT philippebeutels modelingantibodydynamicsfollowingherpeszosterindicatesthathighervaricellazostervirusviremiageneratesmorevzvspecificantibodies |